Danny Gauthier's research while affiliated with Université de Montréal and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
To evaluate safety and visual outcomes after proton beam irradiation (PBI) therapy for subfoveal choroidal neovascularisation (CNV) secondary to causes other than age-related macular degeneration (AMD).
This study is a prospective, unmasked and randomised clinical trial using two dosage regimens, conducted in the Massachusetts Eye and Ear Infirmary...
To evaluate safety and visual outcomes after proton therapy for subfoveal neovascular age-related macular degeneration (AMD).
Randomized dose-ranging clinical trial.
One hundred sixty-six patients with angiographic evidence of classic choroidal neovascularization resulting from AMD and best-corrected visual acuity of 20/320 or better.
Patients were...
To study the safety and efficacy of intravitreal injections of anti-vascular endothelial growth factor antibody fragment (ranibizumab [formerly known as rhuFabV2], Lucentis; Genentech, South San Francisco, Calif) in combination with intravenous verteporfin (Visudyne; Novartis, East Hanover, NJ) photodynamic therapy (PDT) on experimental choroidal n...
Citations
... The characteristics of the Bragg peak mean that the proton beam has the unique advantage of concentrating the maximum radiation dose within a designated target area, while minimizing the radiation to the surrounding tissues [24]. Preliminary evaluations of the treatment of macular CNV with PBI have demonstrated its beneficial effects and safety [10][11][12][25][26][27]. Here, we investigated, for the first time, the effects of PBI in patients with recurrent or refractory PCV. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/273784900943880-1442286815442_Q64/Anne-Marie-Lane.jpg)
... After dilation of the pupils, 1 min after intravenous administration of 0.5 mL/kg of undiluted fluorescein 10%, FFA was performed. To evaluate vascular leakage, the following degrees were used (Goody et al., 2011; Husain et al., 2005; Shen et al., 2004), with some modification: Some samples were excluded from data analysis because of hemorrhage or combined CNV. ...
... Historically, one has to acknowledge the impact of animal models of CNV as the foundation for clinical trials supporting, for example, current standard anti-vascular endothelial growth factor (VEGF) treatment in nAMD. [21][22][23] However, as in many other fields of medicine, translation of preclinical results has also been discouraging, 11,24 and, despite the reporting of safety and tolerability, several studies have failed to reproduce the same promising preclinical efficacy in a clinical setting. [25][26][27] An essential question is the extent to which models of CNV recapitulate CNV formation in the context of human chorioretinal disease such as nAMD. ...
... A high polypoidal lesion regression rate (83.3%) and good visual outcomes were achieved after 12 months. Unlike SRT, proton-beam irradiation (PBI) delivers more than 90% of the radiation dose to the target tissue, thus minimizing damage to the adjacent tissue [10]. This advantage allows fixed-beam irradiation to target the subfoveal neovascular membranes, while delivering a minimal dose to nontarget tissues. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/278916964077572-1443510394311_Q64/Hadi-Zambarakji.jpg)
